Accenture stock slides in New York: traders weigh Sovereign AI deal and fresh Buy call

Accenture stock slides in New York: traders weigh Sovereign AI deal and fresh Buy call

New York, Jan 23, 2026, 14:53 EST — Regular session.

Accenture plc shares dropped 1.2%, hitting $281.73 by 2:53 p.m. EST on Friday, down from Thursday’s close of $285.09. The SPDR S&P 500 ETF showed little movement.

This matters because Accenture is a major player in consulting and IT services, and its stock often reacts to shifts in corporate tech spending. Investors want confirmation that the drive to roll out generative AI is translating into actual contracts, not just trial runs.

On Wednesday, Accenture announced that Sovereign AI, a UK-based firm, had chosen Accenture and Palantir Technologies to develop and expand next-gen AI data centers across Europe, the Middle East, and Africa. The project will leverage Dell’s AI Factory and Nvidia’s infrastructure. Accenture also highlighted research showing 60% of European organizations plan to boost investment in “sovereign AI” — an effort to keep data and models firmly within local regulations — over the next two years. (Accenture Newsroom)

Sovereign AI CEO Bradd Lewis said the company is “poised to provide a solution which future proofs our customers” amid its push to invest in data centers across the UK and EMEA. Accenture’s Bryan E. Rich described the partnership as a move to “forge a new model” for building “safe, secure and resilient AI infrastructure.” (UKTN)

Berenberg kicked off coverage of Accenture with a buy rating and set a $313 price target, highlighting the company’s “premium positioning” amid an AI-driven shift in IT services. The bank noted Accenture’s scale and extensive partner network as key advantages for landing sizable, multi-year transformation projects. (TipRanks)

The stock ended Thursday up 1.56%, outperforming some rivals as IBM slipped while Cognizant and ADP gained, according to MarketWatch data. Trading volume edged just above the 50-day average that session. (MarketWatch)

Yet there’s still uncertainty over how soon Accenture’s Sovereign AI efforts will start generating revenue or impact staffing and delivery expenses. Projects involving multiple parties, especially in government and regulated sectors, often run into delays. Plus, consulting demand can drop sharply if clients cut back on spending.

Accenture’s fiscal second-quarter earnings are up next, with the conference call set for March 19 at 8:00 a.m. EST. Investors will focus on bookings—the dollar value of signed contracts—and the share linked to AI projects. (Accenture)

Stock Market Today

  • Sangamo Therapeutics Price Target Withdrawal Alters Investment Outlook
    January 23, 2026, 3:12 PM EST. Sangamo Therapeutics (SGMO) faces a reset after its price target was withdrawn, signaling increased uncertainty about its gene therapy pipeline and financial outlook. Analysts have not set a new target, reflecting wide possible outcomes and limited visibility on future cash flows. Investors are encouraged to reassess assumptions on development timelines, partnerships, and funding needs. The absence of a price anchor puts more emphasis on qualitative factors like management updates and regulatory milestones. Some investors now assess Sangamo through scenario probabilities rather than fixed estimates, adjusting portfolio positions accordingly. The shift marks a critical juncture in how the market views this biotech name amid evolving clinical and licensing prospects.
Broadcom stock slides as Intel shock ripples through chips ahead of Fed decision
Previous Story

Broadcom stock slides as Intel shock ripples through chips ahead of Fed decision

Apple stock slips as China discounts and memory-chip costs sharpen focus on next week’s earnings
Next Story

Apple stock slips as China discounts and memory-chip costs sharpen focus on next week’s earnings

Go toTop